Revvity, Inc.· RVTY

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

• 

  Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

  WALTHAM, Mass.--(BUSINESS WIRE)-- #AI--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD's human pancreatic beta cell models to Revvity's Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including.

  Sep 9, 2026
• 

  Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?

  Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.

  Sep 4, 2026
• 

  What Makes Revvity (RVTY) a New Buy Stock

  Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  Sep 1, 2026
• 

  Bank of New York Mellon Corp Invests $78.77 Million in Revvity Inc. $RVTY

  Bank of New York Mellon Corp purchased a new stake in Revvity Inc. (NYSE: RVTY) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 707,941 shares of the company's stock, valued at approximately $78,766,000. Bank of New York Mellon Corp

  Aug 26, 2026
• 

  Is the Options Market Predicting a Spike in Revvity Stock?

  Investors need to pay close attention to RVTY stock based on the movements in the options market lately.

  Aug 24, 2026

• RC

  RBC Capital Starts Revvity Inc (RVTY) at Sector Perform

  RBC Capital· Dan Leonard· $135.00
  Sep 1, 2026
• EI

  Revvity price target raised to $125 from $110 at Evercore ISI

  Evercore ISI· Vijay Kumar· $125.00
  Jul 6, 2026
• RW

  Revvity price target lowered to $117 from $125 at Baird

  Robert W. Baird· Catherine Ramsey Schulte· $117.00
  May 6, 2026
• BA

  Revvity downgraded to Equal Weight from Overweight at Barclays

  Barclays· Luke Sergott· $95.00
  Apr 14, 2026
• RW

  Revvity price target raised to $129 from $123 at Baird

  Robert W. Baird· Catherine Ramsey Schulte· $129.00
  Feb 3, 2026